Aprea Therapeutics (APRE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

APRE Aprea Therapeutics

Watchlist

3.050
-0.180-5.57%

Close Dec 20 16:00 ET

3.050
0.0000.00%

Post 20:01 ET

16.58MMarket Cap-1.09P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsDec 16 11:32 ET · Ratings
Aprea Therapeutics' Promising ATRN-119: A Buy Rating Amid Optimized Dosing and Safety Advancements
TipRanksDec 12 14:15 ET · Ratings
Aprea Therapeutics Announces First Patient Dosed in ABOYA-119 Phase 1/2a Trial
TipRanksDec 11 08:35 ET
Express News | Aprea Therapeutics Inc -Anticipates Phase 1 Readout in Second Half of 2025
ReutersDec 11 08:32 ET
Express News | Aprea Therapeutics Announces Twice Daily (Bid) Dosing of Patients in Aboya-119 Clinical Trial of Atrn-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
ReutersDec 11 08:30 ET
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow JonesNov 18 07:51 ET · Ratings

Comments

MadMaverick_

Dec 19 09:51

$Aprea Therapeutics (APRE.US)$
$APRE holding $3 like a champ again! 💪🔥
Just need that volume boost and a push past $3.15 to light the fuse! 🚀
https://chartingdaily.com/advancing-cancer-care-with-dna
Communicated Disclaimer
$PainReform (PRFX.US)$ $AppTech Payments (APCX.US)$ $Micron Technology (MU.US)$ $Nukkleus (NUKK.US)$

Stock_Drift

Dec 5 16:55

After Hours Ticks 5:54pm

$Biodexa Pharmaceuticals (BDRX.US)$ $Kirkland's (KIRK.US)$ $DocuSign (DOCU.US)$ $Aprea Therapeutics (APRE.US)$ $HilleVax (HLVX.US)$ $Asana (ASAN.US)$ $Rubrik (RBRK.US)$ $Cardio Diagnostics (CDIO.US)$ $Gaxos.ai (GXAI.US)$ $Universe Pharmaceuticals (UPC.US)$ $Northann (NCL.US)$ $Primega Group (PGHL.US)$ $The Lion Electric (LEV.US)$ $Zhibao Technology (ZBAO.US)$
📊⚡️📊

Jaguar8

Oct 23 07:33

NEWS

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Aprea Therapeutics (APRE) presented preliminary safety results for its WEE1 inhibitor APR-1051 at the EORTC-NCI-AACR Symposium. The Phase 1 ACESOT-1051 trial is evaluating APR-1051 as monotherapy in advanced solid tumors. Data from two of three enrolled patients show the drug is safe and well-tolerated ...

Stock_Drift

Oct 15 12:43

Unusual Volume Ticks. 1:42pm 10/15

$Wolfspeed (WOLF.US)$ $Wang & Lee Group (WLGS.US)$ $Aprea Therapeutics (APRE.US)$ $Eco Wave Power (WAVE.US)$ $Phunware (PHUN.US)$ $Gritstone Bio (GRTS.US)$ $Aditxt (ADTX.US)$ $Zapata Computing (ZPTA.US)$ $ADVISORSHARES PSYCHEDELICS ETF (PSIL.US)$ $NewGenIvf (NIVF.US)$ $Bright Minds Biosciences (DRUG.US)$

Jaguar8

Jun 17 07:31

NEWS

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Aprea Therapeutics has announced the dosing of the first patient in the ACESOT-1051 Phase 1 trial for their oral WEE1 inhibitor, APR-1051. This study is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors who have unmet medical needs. APR-1051, developed by Aprea, targets the WEE1 kinase, an enzyme involved in the DNA dam...

Trending US Stocks

Symbol Mini Chart % Chg

Unlock the Full List